October 1, 2021

Hypofractionated Radiation Shortens Time to Resection for Soft Tissue Sarcoma

Produces favorable oncologic outcomes, wound healing and quality of life

21-ORI-2350074 CQD 650×450

Treatment for soft tissue sarcoma typically involves a long course of radiation followed by surgery. As a result, it can be weeks or even months before the cancer is removed and treatment is complete.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A new approach is reducing the wait. Instead of five to six weeks of radiation therapy, patients now have the option to undergo five days of hypofractionated external beam radiation. This shorter although higher daily intensity approach has been used in breast, lung and colorectal cancers. Cleveland Clinic is helping lead the charge in the sarcoma space.

“We are shifting the paradigm in treating soft tissue sarcomas,” says Nathan Mesko, MD, Center Director, Orthopaedic Oncology, and Director of Sarcoma Care at Cleveland Clinic. “Our institution and a few others around the country are challenging the tradition that calls for a long course of radiation for this patient population.”

Early outcomes show promise

Complete surgical resection in combination with either neoadjuvant or adjuvant radiation therapy is the mainstay of treatment for soft tissue sarcomas. While there is no significant difference in survival outcomes between neoadjuvant and adjuvant radiation therapy, preoperative radiation is shown to have fewer long-term effects, according to Dr. Mesko.

Conventional neoadjuvant radiation therapy regimens consist of 50 Gy in 25 fractions delivered over the course of five weeks.

“We then wait anywhere from four to six weeks to allow for recovery before we perform surgery,” says Dr. Mesko. “From the time a patient is diagnosed to the time the tumor is removed, it can be three months.”

This can be challenging for a patient, especially those who need to travel for treatment, he notes. By shifting away from this approach, patients now have an option that significantly decreases the length of their treatment, which can improve their quality of life.

Short-course radiation therapy has been used for Cleveland Clinic patients with extremity sarcomas for about four years, according to Dr. Mesko. Patients receive five fractions over the course of five days. Surgery occurs 24 to 72 hours after the last dose of radiation.


Early outcomes reported by Dr. Mesko and colleagues suggest favorable local control and wound healing. In one study published in Advances in Radiation Oncology, 16 patients were treated for sarcomas in their lower extremity, upper extremity or trunk. Most were treated with 30 Gy in five fractions over five consecutive days, followed by resection. The median time to resection following the completion of radiation therapy was one day, and median time from initial biopsy results to the completion of primary oncologic therapy was 20 days.

Of these patients, 10 achieved R0 resection and six achieved R1 resection. Local failure was not reported in any of the 13 patients evaluated. Five patients (31%) had complications with wound healing, but only three (19%) required surgical treatment for it.

Researchers continue to treat patients with hypofractionated preoperative radiation therapy, and long-term follow-up is ongoing.

Two types of short-course radiation for extremity sarcomas

Cleveland Clinic employs two types of short-course radiation for extremity sarcomas.

“We have traditional beam radiation, which involves five days of preoperative treatment followed by resection,” explains radiation oncologist Shauna Campbell, DO. “The other option is brachytherapy. In this approach, we use a small radioactive source to deliver radiation in the tumor bed immediately following surgery.”

Brachytherapy can deliver a higher dose of radiation faster and in a more targeted way compared with standard external beam radiation.

“The advantage of brachytherapy is that the tumor is removed as a first step, and during the same operation, the catheters are laid in the area where the sarcoma was removed,” adds Dr. Mesko. “Radiation is then delivered over five days. A few days after completion of radiation, the wound is closed or reconstructed. In less than two weeks, the entire cancer treatment for localized sarcoma is complete.”


Every patient is discussed in a multidisciplinary fashion to determine which radiation treatment option is most appropriate for their diagnosis.

Investigating use in retroperitoneal sarcomas

Looking beyond extremity sarcomas, a trial is now exploring the use of short-course radiation for retroperitoneal sarcomas.

The trial, “CASE 2720: Prospective Study Evaluating Hypofractionated Radiation Therapy for Retroperitoneal Sarcomas,” is currently accruing patients with histologically confirmed disease whose treatment plan includes neoadjuvant radiation followed by surgery.

“This study will further explore the impact of short-course radiation on sarcoma patients,” notes Dr. Campbell. “This is a life-changing diagnosis, and prolonged treatment courses only add to the stress and anxiety patients are already feeling. While our hope is to see an improvement in outcomes overall, improvements in quality of life are a huge win as well. The field as a whole must continue to look for ways to help ease the burden of treatment, which can improve our patients’ lives exponentially.”

Related Articles

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches